- Home
- BTAI vs NTIP Comparison
BTAI vs NTIP Comparison
Compare BTAI & NTIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- NTIP
- Stock Information
- Founded
- BTAI 2017
- NTIP 1990
- Country
- BTAI United States
- NTIP United States
- Employees
- BTAI N/A
- NTIP N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- NTIP Multi-Sector Companies
- Sector
- BTAI Health Care
- NTIP Miscellaneous
- Exchange
- BTAI Nasdaq
- NTIP Nasdaq
- Market Cap
- BTAI 28.7M
- NTIP 29.5M
- IPO Year
- BTAI 2018
- NTIP 1998
- Fundamental
- Price
- BTAI $0.57
- NTIP $1.33
- Analyst Decision
- BTAI Strong Buy
- NTIP
- Analyst Count
- BTAI 4
- NTIP 0
- Target Price
- BTAI $5.00
- NTIP N/A
- AVG Volume (30 Days)
- BTAI 458.6K
- NTIP 49.6K
- Earning Date
- BTAI 11-14-2024
- NTIP 10-24-2024
- Dividend Yield
- BTAI N/A
- NTIP 7.41%
- EPS Growth
- BTAI N/A
- NTIP N/A
- EPS
- BTAI N/A
- NTIP N/A
- Revenue
- BTAI $2,276,000.00
- NTIP $1,881,000.00
- Revenue This Year
- BTAI $247.03
- NTIP N/A
- Revenue Next Year
- BTAI $88.16
- NTIP N/A
- P/E Ratio
- BTAI N/A
- NTIP N/A
- Revenue Growth
- BTAI 83.25
- NTIP 129.39
- 52 Week Low
- BTAI $0.50
- NTIP $1.24
- 52 Week High
- BTAI $4.32
- NTIP $2.25
- Technical
- Relative Strength Index (RSI)
- BTAI 43.77
- NTIP 50.04
- Support Level
- BTAI $0.50
- NTIP $1.29
- Resistance Level
- BTAI $0.72
- NTIP $1.34
- Average True Range (ATR)
- BTAI 0.08
- NTIP 0.04
- MACD
- BTAI -0.01
- NTIP 0.01
- Stochastic Oscillator
- BTAI 20.70
- NTIP 76.56
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property rights. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.